Majlen Dilweg
Guest
- Name
- M.A. Dilweg MSc
- Telephone
- 071 5272727
- m.a.dilweg@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-4455-3737
I started in 2013 with the Bio-Pharmaceutical Sciences Bachelor at Leiden University. During my studies, I developed a keen interest in the fundamental chemistry part of drug development. Therefore, I performed my first research internship at the LACDR department of Medicinal Chemistry. Combined with my interest in education, I continued with the Bio-Pharmaceutical Sciences Master with a specialisation in education. During a nine months internship at the division of Drug Discovery & Safety, I synthesized and characterized a covalent compound as a novel molecular tool for the adenosine A1 receptor. Subsequently, I started with the ICLON Teaching Master program, which I combined with a position as a chemistry teacher in secondary education. In 2019, after obtaining my Master’s as well as my teaching qualification, I decided to continue in academic research and started my PhD at the division of Drug Discovery & Safety at Leiden University. Under the supervision of prof. dr. A.P. IJzerman and dr. D. van der Es, I will design and synthesize novel molecular tools for the transmembrane protein family of solute carriers (SLCs). With these tools, we want to gain more insight into these physiologically relevant but greatly understudied transport proteins. Besides academic research, I will take on various educational development projects within the Bachelor’s and Master’s program of Bio-Pharmaceutical Sciences.
Guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Medicinal Chemistry
- Veggel L. van, Mocking T.A.M., Sijben H.J., Liu R., Gorostiola González M., Dilweg M.A., Royakkers J., Li A., Kumar V., Dong Y.Y., Bullock A., Sauer D.B., Diliën H., Westen G.J.P. van, Schreiber R., Heitman L.H. & Vanmierlo T. (2024), Still in search for an EAAT activator: GT949 does not activate EAAT2, nor EAAT3 in impedance and radioligand uptake assays, ACS Chemical Neuroscience 15(7): 1424-1431.
- Veggel Lieve van, Mocking Tamara A. M., SijbenHubert J., Liu Rongfang, Gonzalez GorostiolaMarina, DilwegMajlen A., Royakkers Jeroen, LiAnna, Kumar Vijayp, Dong Yin Yao, Bullock Alex, Sauer David B., Dilien Hanne,Westen Gerard J. P. van, Schreiber Rudy, Heitman Laura H. & Vanmierlo Tim (2024), Still in search for an EAAT activator: GT949 does not activate EAAT2, nor EAAT3 in Impedance and radioligand uptake assays, ACS CHEMICAL NEUROSCIENCE 15(7): 1424-1431.
- Wang X. Jespers W. Bongers B.J. Habben Jansen M.C.C. Stangenberger C.M. Dilweg M.A. Gutiérrez-de-Terán H. IJzerman A.P. Heitman L.H. Westen G.J.P. van (2020), Characterization of cancer-related somatic mutations in the adenosine A2B receptor, European Journal of Pharmacology 880: 173126.
- Yang X. Dilweg M.A. Osemwengie D. Burggraaff L. Es D. van der Heitman L.H. IJzerman A.P. (2020), Design and pharmacological profile of a novel covalent partial agonist for the adenosine A1 receptor, Biochemical Pharmacology 180: 114144.